BRAF and melanoma: Ultimately, decisions about adjuvant therapy for resected stage III/IV BRAF mutant melanoma patients should be made on an individual basis, wherein the choice between adjuvant IT and TT takes into consideration potential toxicities, costs and patient preference.27